OUR INVESTORS EXPECT A HEALTHY RETURN on volatile post- pandemic markets

Anderton’s Challenger Impact High Yield Fund primarily invests in early stage companies in venture building model, but is not limited to occasionally target opportunistic corporate finance transactions such as pre-IPOs, IPO and private placements. The positions follow a multi-market, multi-time frame and multi-strategy investment approach. The Fund is not expected to have any bias towards any specific issuer, industrial, geographic or other market sector with preferred coverage in Europe, within Biotechnology, Blockchain, HealthTech, Foodtech, MobilityTech, InformationSecurity, Sports and Supply-chain Tech.

Risk is always attached to investing on the VC/PE markets as well as all equity and equity-type investments. Risk and return are essential elements in selecting investments to the fund portfolio. We are fully conscious that understanding, scaling and managing the risk is crucial to balance your satisfaction with the investment. How do we mitigate the risk? By appointing a licensed portfolio co-manager - Gamma Capital Markets Ltd to act as Investment Manager for Anderton SICAV and all its Sub-Funds. Gamma Capital Markets ensures that the portfolio complies with the risk exposure threshold. By geographical diversification and number of portfolio holdings: Europe, special focus on CEE with approx. 10-15 portfolio companies. By sector diversification and by implementing rigid post-investment risk control.